In this MEDtalk Peter Schmid present updated data for overall survival from Impassion 130-study - a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer.   This 2nd IMpassion130 interim OS analysis confirming clinically meaningful OS benefit of this treatment combination.   

Progression-free and overall survival were significantly improved with first line treatment with pertuzumab, trastuzumab, and docetaxel in 808 pts with HER2-positive metastatic breast cancer.  OS was increased by an unprecedented 15.7 month. In this MEDtalk Sandra M. Swain present the end-of-study analysis with a median follow-up of 99 month (max 120 mo).   

The 2010 Affordable Care Act, ACA, expanded access to insurance and care for many Americans. In this MEdtalks Anna Jo Smith evaluate the impact of the ACA on stage at diagnosis and time to treatment for women with ovarian cancer.   

MEST SETE MEDtalks

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer   Se hele webinar

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

<script src="https://fast.wistia.com/embed/medias/rp2kqsxgnz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rp2kqsxgnz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rp2kqsxgnz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/asco-2019-updated-overall-survival-for-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer/'>Se hele webinar
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

ASCO 2019: First-line treatment of patients with HER2-positive metastatic breast cancer – 4 years of long-term follow-up data

<script src="https://fast.wistia.com/embed/medias/y2w9kplx9l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_y2w9kplx9l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/y2w9kplx9l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: First-line treatment of patients with HER2-positive metastatic breast cancer - 4 years of long-term follow-up data&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/asco-2019-first-line-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-4-years-of-long-term-follow-up-data/'>Se hele webinar
ASCO 2019: First-line treatment of patients with HER2-positive metastatic breast cancer - 4 years of long-term follow-up data

ASCO 2019: Paradigm shift in treatment of metastatic cutaneous squamous cell carcinoma

<script src="https://fast.wistia.com/embed/medias/4rwno0og6n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4rwno0og6n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4rwno0og6n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Paradigm shift in treatment of metastatic cutaneous squamous cell carcinoma&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/asco-2019-paradigm-shift-in-treatment-of-metastatic-cutaneous-squamous-cell-carcinoma/'>Se hele webinar
ASCO 2019: Paradigm shift in treatment of metastatic cutaneous squamous cell carcinoma

ASCO 2019: New promising drug for second-line SCLC patients

<script src="https://fast.wistia.com/embed/medias/eieqe9qnf9.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eieqe9qnf9 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/eieqe9qnf9/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: New promising drug for second-line SCLC patients&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/asco-2019-new-promising-drug-for-second-line-sclc-patients/'>Se hele webinar
ASCO 2019: New promising drug for second-line SCLC patients

In this MEDtalk Kamal Chamoun explain, why nsurance type and regional income are associated with Multiple Myeloma survival. This may be related to affordability of oral antineoplastic medications. Prices have been rapidly escalating and there are well described issues with affordability.   

The Phase III MONALEESA-7 study demonstrated that the addition of ribociclib to a nonsteroidal aromatase inhibitor or tamoxifen + goserelin significantly extended progression-free survival. In this MEDtalk Yen-Shen Lu explain the effect across gene expression subgroups   

Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI).   In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer  Enfortumab vedotin (EV) - an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint inhibitors.  

#Seneste udgivelse

Onkologi

Nr. 37 l april 2019
9. Årgang
  • Metastatisk colorectal cancer
  • Hoved-hals kræft
  • Operation for lungecancer

ASCO på twitter